Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials

Summary

- **Methods**: Total BKZ exposure was 6,324.3 PY (N=2,186; Year 1, Year 2, Year 3, Year 4: 2,053.3 PY [n=2,186], 1,904.3 PY [n=2,013], 1,521.1 PY [n=1,980], 819.5 PY [n=1,695]).
- **Patients**: Included in this analysis were patients who received ≥1 BKZ dose in each of the periods examined (BKZ Total). Data were pooled for all patients who received ≥1 BKZ dose in each of the periods examined (BKZ Total).

**Results**: Data are presented for BKZ Total for the full pooled trial period, and separately for Years 1 (Weeks 0–52), 2 (Weeks 52–104), 3 (Weeks 104–156), and 4 (Weeks 156–208) of BKZ treatment.

- **Summary of exposure and TEAEs**: Included studies

**Figure 1**

**Table 1**

**Table 2**

**Conclusions**: Bimekizumab demonstrated good tolerability and a comparable safety profile over 4 years in patients with moderate to severe plaque psoriasis. EIRs of TEAEs remained constant or decreased with longer bimekizumab exposure over 4 years, with no new safety signals observed.

**Acknowledgments**: This study was funded by UCB Pharma. We would like to thank the patients and their caregivers in addition to the clinical centers and investigators who participated in these studies. The authors thank the study coordinators, the study sites, and the UCB PI team for their support and contribution to these studies.

**References**: 

**Institutions**: UCB Pharma, Morrisville, NC, USA; UCB Pharma, Braine-l’Alleud, Belgium; UCB Pharma, Madrid, Spain; Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy.